news

Pyridostigmine reverses paediatric complications of botulinum toxin therapy

Physicians have reported the first paediatric use of pyridostigmine to reverse complications from botulinum toxin therapy…

Physicians at the Medical University of South Carolina (MUSC) report the first paediatric use of pyridostigmine to reverse complications from botulinum toxin therapy. 

In the study, used a drug called pyridostigmine to treat one paediatric patient experiencing immediate complications from botulinum toxin therapy and another with delayed complications in distant muscles. In both cases, physicians recognised complications early and treated patients with the maximum dose of pyridostigmine appropriate for their weight.

When botulinum toxin is injected into a muscle, it can sometimes travel backwards up nerves and cause unintended paralysis of nearby or distant muscles. In those cases, a drug called pyridostigmine can reverse the paralysis by encouraging muscles to contract.

The official antidote to botulinum toxin is difficult to procure quickly and takes several days to work, while pyridostigmine begins to relieve symptoms within hours. Early treatment is critical for patients who experience complications from botulinum toxin therapy, because symptoms can progress to difficulty swallowing or breathing, according to Dr Lucinda A. Halstead, an Associate Professor in the MUSC Department of Otolaryngology and senior author on the study.

“We see a profound effect in people who can’t swallow. We give pyridostigmine and the effect is within hours,” said Halstead. “Patients are eating again within days.”

In the first case, physicians treated a one-year-old female patient having difficulty swallowing. The patient had a history of aspiration pneumonia, wherein food or saliva is inhaled into the lungs rather than passing into the oesophagus, and she was dependent on a gastrostomy tube implanted in her abdomen for nutrition. During swallowing, one set of muscles called the pharyngeal constrictors must contract to push food toward the oesophagus while another muscle called the cricopharyngeus must simultaneously relax for food to pass into the oesophagus. Physicians observed a poorly relaxing cricopharyngeus and injected the muscle with botulinum toxin to force it to relax so the patient could keep food down.

The next day, however, the patient was admitted to the hospital with choking, vomiting and difficulty breathing. A swallow study revealed that her cricopharyngeus had indeed relaxed, as intended, but that the pharyngeal constrictors that must contract to push food toward the oesophagus had also relaxed. As a result, she was nearly unable to swallow.

The patient was given pyridostigmine through her gastrostomy tube to oppose the effects of botulinum toxin, with the idea that the toxin had spread unintentionally to her neighbouring pharyngeal constrictors, causing them to relax. Two days later, the patient was breathing normally, and she was released on day thirteen after admission. One month later, she had no signs of aspiration and continued to improve. Her gastrostomy tube was removed six months later.

In the second case, an eight-year-old female patient was given an injection of botulinum toxin into her salivary glands to treat excessive salivation. She had displayed an excellent response to the same treatment six months earlier. Seven days after the injection, however, she returned to the hospital, unable to eat or drink without choking. A swallow study showed that her pharynx was not completely clearing itself of food during swallowing. The patient was given oral pyridostigmine and began to rapidly improve. Within a week, she was eating normally again.

This is the first report of physicians treating complications from botulinum toxin therapy with pyridostigmine in pediatric patients. Pyridostigmine is a widely available medication for myasthenia gravis, a disorder that causes muscle weakness. It is safe, but it can cause slowing heart rate in patients with a history of heart problems. It is not an antidote to botulinum toxin, but it does oppose its effects by preventing the breakdown of acetylcholine, which is needed for muscle contraction. In both patients, the drug was given in doses similar to those used to treat myasthenia gravis.

This study emphasizes the need for physicians to be alert to complications from botulinum toxin therapy in children and adults, recognising that such problems might not arise immediately and can appear in muscles distant from the injection site. This recognition is critical in patients who have difficulty swallowing or breathing.

“When a patient has had too much botulinum toxin, there is a point when symptom management strategies are no longer beneficial to the patient,” said Dr Halstead. “Pyridostigmine is an active intervention to modulate the effects of botulinum toxin therapy.”

The findings of the study have been published in The Journal of Pediatrics.

Send this to a friend